Rusfertide
Mar 03, 2023
Polycythemia Vera Treatment: Besremi, Jakafi, and Rusfertide Analysis
There is a wider opportunity for BESREMi; Jakafi is not a direct competitor to Besremi, and there is uncertainty around Rusfertide’s uptake. BESREMi is expanding its horizon in the first-line treatment of Polycythemia vera; JAKAFI’s impressive growth in second-line treatment The polycythemia vera treatment par...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
